

## 240614 IMPROVE-it

### Referenser gällande preventivmetoder och cancerskydd

Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study. *Am J Obstet Gynecol*. 2017;216(6):580 e1- e9. [https://doi: 10.1016/j.ajog.2017.02.002](https://doi.org/10.1016/j.ajog.2017.02.002).

<https://www.sciencedirect.com/science/article/pii/S0002937817301795?via%3Dihub>

Vessey M, Yeates D, Flynn S. Factors affecting mortality in a large cohort study with special reference to oral contraceptive use. *Contraception*. 2010 Sep;82(3):221-9. doi: 10.1016/j.contraception.2010.04.006.

<https://www.sciencedirect.com/science/article/pii/S0010782410001435?via%3Dihub>

Ross CM, Shulman LP. Assessing the Role of Reversible Contraceptives in the Health Care of Women as it Pertains to Cancer Prevention. *Adv Ther* .2017. 34:2412–2421. Doi: 10.1007/s12325-017-0623-7. <https://link.springer.com/article/10.1007/s12325-017-0623-7>

Minalt N , Caldwell A, Yedlicka GM, Joseph S, Robertson SE, Landrum LM, Jeffrey Peipert FJ. Association between intrauterine device use and endometrial, cervical, and ovarian cancer: an expert review. *Am J Obstet Gynecol*. 2023 Aug;229(2):93-100. doi: 10.1016/j.ajog.2023.03.039.

<https://www.sciencedirect.com/science/article/pii/S0002937823002247?via%3Dihub>

Cortessis V, Barrett M, Brown W, Niquelle MS, E, Temuulen MBBS, Perrigo, JL, Tobin J, Zhong C, Zink J, Isiaka V, Muderspach L, Natavio M, McKean-Cowdin R. Intrauterin Device Use and Cervical Cancer risk, a systematic review and meta-analysis. *Obstet Gynecol*. 2017 Dec;130(6):1226-1236. doi: 10.1097/AOG.0000000000002307.

[https://journals.lww.com/greenjournal/fulltext/2017/12000/intrauterine\\_device\\_use\\_and\\_cervical\\_cancer\\_risk.7.aspx](https://journals.lww.com/greenjournal/fulltext/2017/12000/intrauterine_device_use_and_cervical_cancer_risk.7.aspx)

Spotnitz M, Natarajan K, Ryan P, Westhoff C. Relative Risk of Cervical Neoplasms Among Copper and Levonorgestrel-Releasing Intrauterine System Users. *Obstetrics & Gynecology*.2020.135 (2). 319-327. doi: 10.1097/AOG.0000000000003656

[https://journals.lww.com/greenjournal/fulltext/2020/02000/relative\\_risk\\_of\\_cervical\\_neoplasms\\_among\\_copper.11.aspx](https://journals.lww.com/greenjournal/fulltext/2020/02000/relative_risk_of_cervical_neoplasms_among_copper.11.aspx)

Beral V, Doll R, Hermon C, Peto R, Reeves G, Collaborative Group on Epidemiological Studies of Ovarian Cancer Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. *Lancet* 2008;371:303-14. 10.1016/S0140-6736(08)60167-1

[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(08\)60167-1/abstract](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)60167-1/abstract)

Iversen L, Fielding S, Lidegaard Ø, Mørch LS, Skovlund CW, Hannaford PC. Association between contemporary hormonal contraception and ovarian cancer in women

of reproductive age in Denmark: prospective, nationwide cohort study. *BMJ*. 2018 Sep 26;362:k3609. doi: 10.1136/bmj.k3609. PMID: 30257920; PMCID: PMC6283376.  
<https://bmj.com/content/362/bmj.k3609>